
Aprea Therapeutics Collaborates with MD Anderson Cancer Center to Investigate APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)
Aprea Therapeutics and MD Anderson Cancer Center Collaborate to Explore Potential of APR-1051 in Treating Head and Neck Squamous Cell Carcinoma Doyletown, PA, USA, March 11, 2025 – Aprea Therapeutics, Inc., a pioneering biopharmaceutical company specializing in the development of innovative cancer therapies that target cancer cell vulnerabilities while minimizing healthy cell damage, has recently…